Sandell Jacquelyn Fahey Sells 5,999 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Voyager Therapeutics Price Performance

Shares of Voyager Therapeutics stock opened at $7.04 on Friday. The firm has a market cap of $383.89 million, a PE ratio of -140.77 and a beta of 0.91. Voyager Therapeutics, Inc. has a 1 year low of $5.71 and a 1 year high of $11.72. The stock has a fifty day moving average price of $6.72 and a 200-day moving average price of $7.88.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. The business had revenue of $29.58 million during the quarter, compared to the consensus estimate of $11.52 million. During the same quarter last year, the company posted ($0.51) earnings per share. As a group, equities analysts anticipate that Voyager Therapeutics, Inc. will post -1.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. raised its position in shares of Voyager Therapeutics by 49.6% in the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock valued at $37,000 after purchasing an additional 1,300 shares during the period. Plato Investment Management Ltd purchased a new position in shares of Voyager Therapeutics during the 1st quarter valued at $38,000. SG Americas Securities LLC bought a new stake in Voyager Therapeutics during the second quarter valued at $85,000. China Universal Asset Management Co. Ltd. increased its stake in Voyager Therapeutics by 104.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,404 shares of the company’s stock worth $97,000 after acquiring an additional 5,311 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new stake in shares of Voyager Therapeutics in the 1st quarter valued at about $101,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on VYGR shares. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, August 20th. Wedbush lowered their price target on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.83.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.